Introduction

Inhibitors of the renin-angiotensin system (RAS) are widely used clinically for their beneficial effects of preserving cardiac function (1, 2), and also for conserving renal function (3). Several large-scale trials have verified that angiotensin-converting-enzyme inhibitors (ACEI) suppress the progression of renal function deterioration in type 1 diabetes (4), and that angiotensin-II receptor blockers (ARB) prevent the aggravation of renal function in type 2 diabetes (5-7). Currently, RAS inhibitors are one of the most widely used antihypertensive agents in diabetic patients. On the other hand, hyperkalemia is a well recognized adverse drug reaction of RAS inhibitors. Further, hyperkalemia is known
to occur at higher rates in patients with lowered renal function or diabetes (8, 9) . Apart from RAS inhibitors, other agents such as beta-blockers are also well known to increase serum potassium levels (10) . Despite 
Patients and Methods
All patients treated at the Departments of Nephrology and
Results
Patient background
The background of 9,117 patients is shown in 
Relation between renal function and serum potassium level
The relation between serum creatinine level and serum potassium level is shown in Fig. 1 . The serum potassium level increased significantly accompanying the increase in serum creatinine level (ANOVA: p<0.001).
Serum potassium level according to the presence or absence of diabetes
The mean serum potassium level was 4 
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The distribution of serum creatinine levels and serum potassium levels in diabetic and non-diabetic patients is shown in Fig. 2 
Relation between the serum potassium level and drugs potentially elevating serum potassium level
The relation between the serum potassium level and ad- 
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ministration of drugs that potentially increase serum potassium level is shown in
Effect of the combination of diabetes and RAS inhibitor prescription on serum potassium level
Since diabetes and RAS inhibitor prescription individually were proven to increase the serum potassium level, the effect of a combination of these two factors was examined (Fig. 5) . For both ACEI and ARB, among patients with a serum creatinine level below 1.5 
mg/dL, the serum potassium level increased in the presence of diabetes or drug administration compared to no diabetes and no drug administration, and was significantly increased with a combination of diabetes and RAS inhibitor administration. Of 8,743 patients with a serum creatinine level below 1.5 mg/dL, 541 had serum potassium levels above normal (5.0 mEq/L or above). Among them, 165 patients had no diabetes and received no ACEI or ARB, and the remaining 376 patients (70%) had diabetes or were receiving AECI or ARB.
In patients with a serum creatinine level of 1.5 mg/dL and above, although the serum potassium levels were high overall, no significant differences were observed between the four groups (Fig. 5) . The large variation observed in patients given ACEI was probably caused by the small number of patients.
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Relation between serum potassium level and age or gender
The relation between age and serum potassium level is shown in Fig. 6 
Relation between serum potassium level and various factors
Step 
Discussion
In the human body, potassium present in extracellular fluid constitutes approximately 2% of the total potassium. In healthy adults, the serum potassium level is strictly controlled within the narrow range of 3.5 to 5.0 mEq/L, irrespective of the dietary potassium intake. This is achieved by maintaining the balance between the amount of intake and amount excreted via the kidney and intestinal tract, and the balance between intracellular and extracellular concentrations. Renal elimination is the main excretion route of potas-
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Hyperkalemia affects the excitation conduction system of the heart. Further increase of blood potassium is associated with risks of severe arrhythmia. Moreover, the effect on the excitation conduction system does not always parallel the serum potassium level, and individual variation is said to be great. Therefore, controlling serum potassium level within a safe range is of great importance. In addition to lowered renal function, diabetes is a well known condition that increases the risk of hyperkalemia. Extracellular potassium is taken up intracellularly by insulin action. In diabetes in which the insulin action is insufficient or deficient, the serum potassium level increases (11, 12 
